Evidence map›Paper›PMID 26061798›Full record

ArticleAIDS patient care and STDs2015

Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.

Julia L Marcus, Wendy A Leyden, Chun R Chao, Lanfang Xu, Charles P Quesenberry, Phyllis C Tien, Daniel B Klein, William J Towner, Michael A Horberg, Michael J Silverberg

Open access · greenAbstract read
In one paragraph

Article in AIDS patient care and STDs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Effect of Traditional Chinese Medicine Therapy on the Trend in CD4Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Julia L Marcus1 Kaiser Permanente Northern California , Oakland, California.
Wendy A Leyden1 Kaiser Permanente Northern California , Oakland, California.
Chun R Chao2 Kaiser Permanente Southern California , Pasadena, California.
Lanfang Xu2 Kaiser Permanente Southern California , Pasadena, California.
Charles P Quesenberry1 Kaiser Permanente Northern California , Oakland, California.
Phyllis C Tien3 University of California , San Francisco, California, and Department of Veterans Affairs Medical Center, San Francisco, California.
Daniel B Klein4 Kaiser Permanente Northern California , San Leandro, California.
William J Towner5 Kaiser Permanente Southern California , Los Angeles, California.
Michael A Horberg6 Mid-Atlantic Permanente Research Institute , Rockville, Maryland.
Michael J Silverberg1 Kaiser Permanente Northern California , Oakland, California.
Kaiser Permanente · USSan Francisco VA Medical Center · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Hepatitis C virus (HCV) co-infection and biological sex may each affect response to antiretroviral therapy (ART), yet no studies have examined HIV-associated outcomes by both HCV status and sex. We conducted a cohort study of HIV-infected adults initiating ART in Kaiser Permanente California during 1996-2011. We used piecewise linear regression to assess CD4 changes by sex and HCV status over 5 years. We used Cox regression to estimate hazard ratios (HR) by sex and HCV status for HIV RNA <500 copies/mL over 1 year, and for AIDS and death over the follow-up period. Among 12,865 subjects, there were 154 HIV/HCV-co-infected women, 1000 HIV/HCV-co-infected men, 1088 HIV-mono-infected women, and 10,623 HIV-mono-infected men. CD4 increases were slower in the first year for HIV/HCV-co-infected women (75 cells/μL) and men (70 cells/μL) compared with HIV-mono-infected women (145 cells/μL) and men (120 cells/μL; p<0.001). After 5 years, women had higher CD4 than men in both HIV-mono-infected (598 vs. 562 cells/μL, p=0.003) and HIV/HCV-co-infected individuals (567 vs. 509 cells/μL, p=0.003). Regardless of sex, HIV/HCV co-infection was associated with 40% higher mortality [95% confidence interval (CI): 1.2-1.6] compared with HIV mono-infection, but was not associated with AIDS (HR 1.1, 95% CI: 0.9-1.3) or achieving HIV RNA <500 copies/mL (HR 1.0, 95% CI: 0.9-1.1). HIV/HCV-co-infected men and women have slower CD4 recovery after starting ART and have increased mortality compared with HIV-mono-infected men and women. HCV should be aggressively treated in HIV/HCV-co-infected adults, regardless of sex.

Indexed as

CD4 Lymphocyte CountAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCaliforniaCohort StudiesCoinfectionFemaleHepacivirusHepatitis CHIV InfectionsHumansIncidenceKaplan-Meier EstimateMaleAnti-Retroviral Agents

Identifiers

PMID26061798
PMCPMC4808272
OpenAlexW1474931616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.